XBRANE BTU Stock Overview
Xbrane Biopharma AB (publ), a biotechnology company, develops, manufactures, and sells biosimilars.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Xbrane Biopharma AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr11.60 |
| 52 Week High | kr19.00 |
| 52 Week Low | kr11.00 |
| Beta | 1.14 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -3.73% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| XBRANE BTU | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -8.7% | 2.8% | 1.4% |
| 1Y | n/a | -3.1% | 8.6% |
Return vs Industry: Insufficient data to determine how XBRANE BTU performed against the Swedish Biotechs industry.
Return vs Market: Insufficient data to determine how XBRANE BTU performed against the Swedish Market.
Price Volatility
| XBRANE BTU volatility | |
|---|---|
| XBRANE BTU Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in SE Market | 13.3% |
| 10% least volatile stocks in SE Market | 3.6% |
Stable Share Price: XBRANE BTU has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine XBRANE BTU's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 93 | Martin Amark | www.xbrane.com |
Xbrane Biopharma AB (publ), a biotechnology company, develops, manufactures, and sells biosimilars. The company is developing Ximluci, a ranibizumab biosimilar used for the treatment of wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults. Its pre-clinical phase products include BIIB801, a biosimilar candidate for the treatment of rheumatoid arthritis, psoriasis, Crohn’s disease, and axial spondylitis; Xdivane for skin cancer, lung cancer, renal cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xtrudane for brain cancer, melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; and Xdarzane for multiple melanoma.
Xbrane Biopharma AB (publ) Fundamentals Summary
| XBRANE BTU fundamental statistics | |
|---|---|
| Market cap | kr14.83m |
| Earnings (TTM) | -kr322.03m |
| Revenue (TTM) | kr238.73m |
0.1x
P/S Ratio0.0x
P/E RatioIs XBRANE BTU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XBRANE BTU income statement (TTM) | |
|---|---|
| Revenue | kr238.73m |
| Cost of Revenue | kr203.34m |
| Gross Profit | kr35.39m |
| Other Expenses | kr357.42m |
| Earnings | -kr322.03m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Mar 27, 2024
| Earnings per share (EPS) | -10.80 |
| Gross Margin | 14.82% |
| Net Profit Margin | -134.89% |
| Debt/Equity Ratio | 102.4% |
How did XBRANE BTU perform over the long term?
See historical performance and comparison